I]-SDF-1 ligand competition binding assays. One of the synthesized compounds was particularly active in blocking SDF-1-induced breast cancer cell motility, proliferation and downstream signaling activation in different breast cancer cell models and co-culture systems. Conclusion: The newly synthesized compounds represent suitable leads for the development of innovative therapeutic agents targeting CXCR4.
CXCR4 (C-X-C chemokine receptor type 4), also known as CD184 (cluster of differentiation 184) or fusin, is a seven transmembrane G-protein coupled receptor (GPCR) belonging to rhodopsin-like GPCR family [1, 2] . CXCR4, first identified as one of the two co-receptors required for the fusion of HIV envelope with the membrane of the targeted cell, was found to be widely expressed in the hematopoietic and immune systems, where it is likely involved in several physiological and pathological processes [3, 4] .
The natural CXCR4 ligand was recognized to be the Stromal Derived Factor-1 (SDF-1), an eight-kDa homeostatic chemokine peptide also known as CXCL12, which promotes chemotaxis after binding the receptor [5] . The SDF-1/CXCR4 interaction plays a key role in pathological processes, such as HIV infection, inflammation and cancer onset and progression, thus representing an appealing target for the development of innovative broad-spectrum therapeutics [6, 7] .
The mounting evidence of the crucial role played by CXCR4 in several diseases has encouraged the development of compounds that are able to modulate its biological activity. In the past few years, numerous compounds belonging to different chemical classes, have demonstrated capacity to block SDF-1/CXCR4 interaction ( Figure 1) . Some of these compounds are currently under clinical trials for the treatment of various diseases including cancers, hematologic and vascular diseases, HIV infection, and other immune system disorders involving the modulation of the SDF-1/CXCR4 axis, such as rheumatoid arthritis and lupus [8] .
The first identified CXCR4 antagonists were peptide derivatives that, despite the unfavorable pharmacokinetics and metabolic instability, have been the starting point for building up a pharmacophore model subsequently adopted for the design of simpler non-peptide antagonists [8, 9] Among the non-peptide ligands, a macrocyclic "bicyclam" derivative, called AMD3100, also known as Plerixafor (1) , has been the first CXCR4 antagonist approved by the FDA for diseases involving the mobilization of hematopoietic stem cells [10] and presently it is in advanced clinical trials for other pathological conditions [11] [12] [13] [14] [15] . Despite the noteworthy potency, the clinical applicability of this compound is yet limited by a poor bioavailability due to its high overall positive charge at physiologic pH.
Furthermore, the small molecule AMD070 (2) , the lead of a series of compounds containing at the same time a benzimidazole and a tetrahydroquinoline moiety in their structure, demonstrated a remarkable antagonistic activity after oral administration and it is currently under advanced clinical investigation for the prophylaxis of HIV infection [16] [17] [18] . The evolution in the search of alternative structure for CXCR4 antagonists brought to the identification of poly-substituted indoles, among them compound 3 represents the most promising prototype active in human CXCR4 transfected Chinese hamster ovary (CHO) cells in a [
125 I]-SDF-1 radio-ligand assay [19] .
These compounds were abandoned due to their high protonation degree 'in vivo', which precludes an adequate tissues distribution. However, various groups functionalizing the indole nucleus could yet guarantee spatial requirements for key interactions in the previously reported pharmacophore model, as
shown by molecular modeling [20] . A further improvement in the definition of CXCR4 receptor was the discovery of the orally active isothiourea ligand IT1t (4), which was co-crystallized with the receptor [21, 22] .
Herein, we report the identification of a small series of CXCR4 antagonists based on a 2-(1H-indol-1-yl)-N'-arylbenzohydrazide moiety (FIL1-3, Figure 2 ) with typical small molecule drug characteristics reflecting potential favorable pharmacokinetics and many possibilities to be optimized. Since the chemokine SDF-1α and its cognate receptor CXCR4 play a crucial role in breast cancer spread and progression [23, 24] , the effects of synthesized compounds have been tested in different breast cancer cell models and in co-culture systems by using specific biological assays, such as cell proliferation and woundhealing assays, where they revealed interesting anticancer properties.
In particular, one of the tested compounds, FIL2, was particularly active in blocking SDF-1α-dependent cell motility, proliferation and downstream signaling activation in estrogen-receptor negative and positive breast cancer cells as well as in experimental cell models for acquired endocrine resistance. A specific [ 125 I]-SDF-1α binding assay has confirmed that the above properties were unambiguously due to CXCR4 inhibition.
This compound was also able to inhibit the effects of cancer-associated fibroblasts (CAFs), key players in the breast tumor microenvironment, on cancer progression.
Based on all the promising results we obtained, the newly synthesized compounds could be considered leads for the development of new selective CXCR4 antagonists as novel tools for the treatment of breast cancer and other CXCR4-related diseases.
MATERIALS AND METHODS

Molecular modelling and docking simulations
The molecular modelling simulations were performed on an Apple Mac pro 2.66 GHz Quad-Core Intel Xeon, Running Ubuntu 12.04. The CXCR4 protein was downloaded from the Protein Data Bank, accession code: 3ODU [20] and prepared using the Protein Preparation Wizard tool of Maestro [25] . Putative inhibitors were built and prepared in Maestro and docked with GLIDE, using the SP mode. Images were created using MOE [26] .
Chemical synthesis
General experimental information is reported in ref. 27 . The purity of FIL1-3 was > 96 %, as determined by HPLC.
2-(5-Bromo-1H-indol-1-yl)-N'-phenylbenzohydrazide (FIL1)
To a stirred solution of 2-(5-bromo-1H-indol-1-yl)benzoic acid 1 [27] .
2-(5-Bromo-1H-indol-1-yl)-N'-(quinoxalin-2-yl)benzohydrazide (FIL3)
This compound was prepared following the procedure applied for FIL1 starting from quinoxalin-2-yl- long-term estrogen-deprived cells (LTED) were derived from MCF-7 after six-month estrogen deprivation were obtained as previously described [28] . Subconfluent cell cultures, synchronized for 48 hours in medium without phenol red and serum, were used for all experiments.
Biological materials and methods
Reagents and antibodies
CAF isolation and conditioned medium systems
Human cancer-associated fibroblasts (CAFs) were obtained from three specimen of human primary breast cancers as described [29] . Briefly, following digestion of small tumor pieces (collagenase 500 U/mL in Hank's balanced salt solution, at 37°C for 2 hours) and differential centrifugation (90 g for 2 minutes), the supernatant containing CAFs was centrifuged (500 g for 8 minutes), resuspended, and cultured in RPMI-1640 medium supplemented with 15% Fetal Bovine Serum, and antibiotics. CAFs between 4-10 passages were used, tested by mycoplasma-presence, authenticated by morphology and FAP and α-SMA expression.
For generation of conditioned media, CAFs were incubated with medium without phenol red and serum for 48-72 hours. Conditioned media were collected, centrifuged to remove cellular debris and utilized in respective experiments.
RT-PCR assays
Total cellular RNA was extracted using TRIZOL reagent as suggested by the manufacturer. The purity and integrity were checked spectroscopically and by gel electrophoresis before carrying out the analytical procedures. Two microgram of total RNA were reverse transcribed in a final volume of 20 µL using a RETROscript kit as suggested by the manufacturer. The cDNAs obtained were amplified by PCR using the following primers:
CTCAACATCTCCCCCTTCTC-3' (36B4 forward) and 5'-CAAATCCCATATCCTCGTCC-3' (36B4
reverse). Negative controls containing water instead of first strand cDNA were utilized.
Wound-healing assays
For the measurement of cell migration during wound healing, confluent cell cultures were incubated in phenol-red and serum-free medium for 24 hours before the beginning of the experiment. Cell monolayers were then scraped, washed to remove debris and treated as indicated in the respective experiments. Wound closure was monitored over 24 hours. Cells were then fixed, stained with Comassie Brillant Blue and photographed after wounding under phase contrast microscopy at 10X magnification. Pictures represent one of three-independent experiments.
Cell proliferation assays
MTT assays. Cells (2 x 10 4 cells/well) were plated in 24-well plates and treated as indicated for 3 days. The
MTT assay was performed as the following: 100 µL MTT solution in PBS (2 mg/mL) was added into each well and allowed to incubate at 37°C for 2 hours followed by media removal and solubilization in 500 µL dimethyl sulfoxide (DMSO). After shaking the plates for 15 minutes, the absorbance at 570 nm was measured in each well, including the blanks. Cell proliferation was expressed as fold change relative to vehicle-treated cells. A minimum of three experiments, containing eight different doses of FIL2 in triplicate, was combined for IC50 calculations. The absorbance readings were used to determine the IC50 using GraphPad Prism 4 (GraphPad Software). Briefly, values were log-transformed, normalized, and nonlinear regression analysis was used to generate a sigmoidal dose-response curve to calculate IC50 values.
Soft agar growth assays. Cells (10 4 /well) were plated in 0.35% agarose with 5% charcoal stripped-FBS in phenol red-free media (4 mL), with 0.7% agarose base in six-well plates. After two days, media containing vehicle or indicated treatments were added to the top layer, and replaced every 2 days. After 14 days, 300 µL of MTT reagent was added to each well and incubated at 37°C for 4 hours. Plates were then placed at 4°C overnight and colonies > 50µm diameter from triplicate assays were counted. The data are representative of three independent experiments, each performed in triplicates.
Immunoblot analysis
Total protein lysates were subjected to SDS-PAGE as described [30] . Briefly, cells were harvested in cold µL wash buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 500 mM NaCl, 5 mM MgCl2). Bound ligands were determined by standard gamma counting techniques. At least three independent experiments were performed. The binding data were analyzed by nonlinear regression using the GraphPad PRISM program.
Statistical analysis
Data were analyzed for statistical significance using two-tailed student's Test, GraphPad-Prism4 software.
Standard deviations (S.D.) were shown.
RESULTS AND DISCUSSION
Design and synthesis
The isothiourea ligand IT1t (4),
, showing an IC50 = 48 nM in CXCR4 radioligand binding assay, was fruitfully used during the mapping of the active binding site of the protein, as already mentioned [20] .
The rationale behind the design of the hereby-reported inhibitors was guided by two considerations: in silico analysis of the interactions between IT1t and CXCR4 in the crystal complex and the synthetic feasibility of the newly designed compounds using established procedures. In particular, we were interested in a chemical scaffold we could easily prepare using our recently reported method [27] . All the compounds designed using Among the attempted aryl substituents, the pyrazine gave best results probably due to the possibility to interact further with Arg183 ( Figure 3B ). The three studied compounds (FIL 1-3) were obtained in moderate yields starting from a common intermediate, the 2-(5-bromo-1H-indol-1-yl)benzoic acid 1, whose preparation was recently described [27] .
The acid 1 was coupled with a proper hydrazine derivative by action of 1,1'-carbonyldiimidazole (CDI) in DMF to give compounds FIL1, FIL2 and FIL3 in 22, 50 and 37% yield, respectively (Figure 4) . 
FIL2 compound blocks SDF-1α-dependent cell motility, proliferation and downstream signalling activation in MDA-MB-231 breast cancer cells
It has been reported that the chemokine SDF-1α and its cognate receptor CXCR4 are expressed in breast carcinoma tissues and in breast cancer cell lines, and that cell clones isolated from metastatic sites (e.g., bone or lungs) exhibit higher levels of CXCR4 than the parental cells [31] [32] [33] . Prior to evaluating the biological activity of the CXCR4 antagonists, we analyzed SDF-1α and CXCR4 expression in estrogen receptor (ER)- Figure 5B showed that FIL1 and FIL3 did non affect cell motility at all the doses tested, while FIL2 was able to inhibit migration at concentrations as low as 10nM. Therefore, in agreement with the docking simulation, the in vitro evaluations of the CXCR4 inhibitory efficacy on cell motility also resulted in the selection of the antagonist FIL2 for the subsequent studies. Next, we assessed the effects of increasing concentrations of FIL2 compound on breast cancer cell proliferation ( Figure 5C ). We observed that FIL2 treatment for 72 hours significantly reduced cell viability in MDA-MB-231 cells at all the doses tested, with IC50 values of 49.4 µM (95% Confidence Intervals, 30.1-81.2 µM). The activity of FIL2 compound was also evaluated using soft agar anchorage-independent growth. Consistently with MTT assays, FIL2 treatment decreased colony formation in MDA-MB-231 cells ( Figure 5D ). In contrast, FIL2 did not elicit any significant growth inhibitory effects on MCF-10A non-tumorigenic breast epithelial cells ( Figure 5E ).
Taken together, these results showed that the compound FIL2 inhibits cell growth and migratory potential of highly invasive MDA-MB-231 breast cancer cells, interfering with the autocrine effects of SDF-1α /CXCR4
system in these cells. The behavior of tumor cells seems to be regulated not only by cell autonomous signals, but it also relies on heterotypic signals coming from surrounding myofibroblast stromal cells, able to create a specific and local microenvironment to tightly control breast cancer proliferation and differentiation. Indeed, fibroblasts adjacent to primary breast tumors have higher expression of SDF-1α than those of normal breast tissue and through this paracrine signaling, CXCR4 may promote local tumor cell proliferation, motility, and invasion [36, 37] . Therefore, we examined the ability of FIL2 compound to inhibit breast cancer cell proliferation and motility promoted by cancer-associated fibroblasts (CAFs). To this aim, CAFs were isolated from biopsies of primary breast tumors and coculture experiments were performed to create 'in vitro' conditions that can mimic the complex 'in vivo' microenvironment [29, 38] . Both MDA-MB-231 and MCF-7 breast cancer cells were incubated with phenol-red and serum-free medium (-), or CAF-derived conditioned media (C.M.) in the presence or not of FIL2 compound and growth and motility were evaluated ( Figure 9) . As previously demonstrated [29] , CAF C.M. significantly increased colony numbers and motility of breast cancer cells.
Interestingly, treatment with FIL2 compound attenuated growth and migration-promoting activities of CAF C.M. It has been recently reported that enhanced CXCR4 signaling is sufficient to drive ER-positive breast cancers to an endocrine therapy-resistant phenotype, highlighting CXCR4 signaling as a rational therapeutic target also for the treatment of ER-positive, estrogen-independent breast carcinoma [39, 40] . Therefore, as a final step of this study, we evaluated whether FIL2 compound was able to affect the progression of hormoneindependent and therapeutic-resistant breast cancer cell lines, using other two additional breast cancer cellular models. In particular, as experimental cell models for acquired resistance, we used: 1) tamoxifenresistant (TR) cells obtained from MCF7 cells cultured with 4-OH tamoxifen over a period of 12 months; 2) MCF7 LTED cells, which gradually acquired aromatase inhibitor resistance upon culture in estrogen/steroid-free conditions [28] . As shown in Figure 10A&10B , we found increased SDF-1α and CXCR4 expression in TR cells and LTED cells compared to parental MCF-7 breast cancer cells. In agreement with a previous study [30] , resistant cells exhibited a higher basal non-stimulated growth and motility ( Figure 10C&10D ).
Treatment with SDF-1α or CAF-derived conditioned medium resulted in an enhancement of growth and motility of TR and LTED cells and, again, FIL2 compound had a significant inhibitory effect in basal as well as SDF-1α and C.M.-stimulated conditions. 
CONCLUSION
CXCR4 plays a role in several pathophysiological conditions such as cancer, altered immune conditions and HIV infection, hence chemical agents able to prevent the interaction between this receptor and its endogenous ligand SDF-1 might result useful in the management of a number of pathologies [5] [6] [7] [8] [9] . Despite the huge number of identified CXCR4 antagonists, most of them show inadequate bioavailability, that represents the bigger limit to a clinical application. Thus, only a few compounds have so far entered clinical trials [11] [12] [13] [14] [15] . Among the small-molecule antagonists, indole based compounds, suitably modified, seem to meet pharmacokinetic requirements and optimal features to interact with the target.
In the present study, we describe the design and the synthesis of three novel molecules namely FIL1-3 investigated for their capability to interact with CXCR4. In particular, one of the derivatives shows the ability to bind to CXCR4 as revealed by molecular docking and whole cell-based [ Since breast cancer progression has been correlated to the SDF-1α-CXCR4 signaling axis, specific agents able to prevent this interaction, could result of great interest for the management of such a type of cancer.
Based on these findings, we may consider FIL-2 as a lead for the development of a new class of selective antagonist ligands of CXCR4 that may be useful in order to better assess the biological function of this receptor. In addition, the CXCR4 antagonism may represent a starting point for the development of novel therapeutics for the treatment of breast cancer and other diseases in which the receptor is involved.
FUTURE PERSPECTIVE
The role played by the interaction of CXCR4 and its natural ligand SDF-1 in several types of tumors, including breast cancer, as well as in other diseases is clearly recognized. This suggests that CXCR4 represents a promising target for the development of innovative therapeutics and the identification of FIL2, as a selective targeting CXCR4 lead compound, may help the discovery of effective CXCR4 antagonists to be proposed to clinical practice. Moreover, the possibility to prepare a FIL2 79 Br-or 81 Br-radiolabeled derivative to be used as functional biomarkers in early diagnosis, disease prevention, and drug response may represent a further applicative development for the class of compounds herein described.
EXECUTIVE SUMMARY
CXCR4 Inhibition
Inhibition of CXCR4 represents a promising therapeutic approach in the treatment of breast cancer and other diseases involving this receptor.
Lead identification and synthesis
A new selective CXCR4 antagonist has been identified and could be useful for a rational design of broadspectrum therapeutics.
Binding assay A whole cell-based [
125 I]-SDF-1α ligand competition binding assay was accomplished in order to verify that FIL2 binds to the CXCR4 receptor as hypothesized by molecular docking prevision.
DEFINED KEY TERMS
Docking simulation:
Computational simulation technique used to predict the binding orientation of a candidate ligand into the active site of the target protein.
Mapping of the active binding site:
The assignment of chemical features for the definition of topology in the interaction site of a receptor.
Poly-substituted indoles:
Molecules based on an indole scaffold bearing substituents capable to bind specific groups of the active site of a target molecule.
Acquired endocrine resistance:
Despite the significant advances in the treatment of breast cancer following the introduction of endocrine therapy (tamoxifen and aromatase inhibitors), in many estrogen receptor-positive breast tumors drug resistance develops during treatment leading to disease progression (acquired resistance).
Tumor microenvironment:
The behavior of malignant cells seems to be dependent not only on cell autonomous signals, but it also relies on heterotypic signalings deriving from surrounding stromal cells, able to generate a microenvironment to tightly control breast tumor progression. Among the stromal cells, cancer-associated fibroblasts (CAFs) play a crucial role in determining cancer proliferation and differentiation.
Soft agar growth assay:
The soft agar colony formation assay is a technique used to evaluate cellular anchorage-independent proliferation in vitro. This assay is considered to better reflect in vivo three-dimensional tumor growth.
Ligand binding assay:
Detection method used to evaluate the interactions that occur between two molecules, such as a receptor and its ligands.
Coculture experiments:
Coculture experiments were performed by incubation of breast cancer cells with CAF-derived conditioned media. This allows to create in vitro conditions that can mimic the complex in vivo microenvironment.
